00:00The psoriasis disease is a disease caused by many different domains that can be involved.
00:11Just think of the cuticle, the joints, the tendons, the nails, the spine.
00:17All this together often has comorbidities, such as cardiovascular disease, for example.
00:23It is clear that we must consider this disease as a unicum, as a story that every patient has to tell
00:30and that we doctors must interpret it as a whole and not look at it through the window of the clinic.
00:37Bhimikizumab is a new biotechnological drug that is added to the numerous drugs that we already have for the treatment of this disease.
00:45The novelty is in the ability of the drug to have a more complete action,
00:52because it is able to inhibit not only a cytokine in its small part, but to inhibit this cytokine in two parts,
01:00therefore two components of the cytokine itself.
01:02So it is certainly an improvement in the ability to endure a fuller response.
01:07What changes?
01:08It changes that we always need new drugs for our patients
01:12because we have patients who do not respond correctly to the drugs we have.
01:16Second, having a drug that is more complete, of course,
01:21improves our ability to induce a complete response in these patients, such as remission.
01:27We have a series of drugs that can be more or less active at the level of the dermatological component,
01:32at the level of the, let's say, articular component or of the spine.
01:37What we are doing now is working closely with rheumatologists and dermatologists
01:42to identify the best time to use the drugs.
01:46Bimikizumab is a drug that works extremely well on the dermatological component,
01:51like all 17 inhibitor interleukins,
01:54but it also works very well on the skeletal component,
01:58inducing an excellent response in terms of remission in patients who have the particularly active articular component.
02:05From a rheumatological point of view, the drug, the most interesting result
02:10is related to the number of patients who achieve a result called MDA,
02:15that is, Minimal Disease Activity.
02:17This MDA, which is a situation very close to complete remission,
02:21is achieved in a very high percentage of patients,
02:24so this gives us great hope in real life
02:27to achieve the same result in the patients we see in the ward.
Comments